Alejandro Balsa1, Raimon Sanmarti2, José Rosas3, Victor Martin4, Ana Cabez5, Susana Gómez6, María Montoro6. 1. Department of Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain. 2. Arthritis Unit, Department of Rheumatology, Hospital Clinic de Barcelona and IDIBAPS, Barcelona, Spain. 3. Department of Rheumatology, Hospital Marina Baixa, Villajoyosa, Alicante, Spain. 4. Biostatistics, Pfizer España, Madrid, Spain. 5. Medical Affairs, Pfizer España, Madrid, Spain. 6. Inflammation Rheumatology, Medical Department, Pfizer SLU, Madrid, Spain.
Abstract
Objectives: The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response. Methods: This was a cross-sectional, observational study of patients with active RA or SpA experiencing secondary failure to etanercept (ETN), infliximab (INF) or adalimumab (ADL). Concomitant non-biologic DMARDs were permitted. Serum anti-TNF and ADA levels were measured with two-site ELISA. Results: Among 570 evaluable patients, those with RA (n = 276) were mostly female (80 vs 39%), older (56 vs 48 years), received concomitant DMARDs (83 vs 47%) and had maintained good clinical disease control for longer (202 vs 170 weeks) compared with patients with SpA (n = 294). ADA were found in 114/570 (20.0%) patients; 51/188 (27.1%) against INF and 63/217 (29.0%) against ADL; none against ETN. Of these 114 patients, 92 (81%) had no detectable serum drug concentrations. Proportionately more patients with SpA (31.3%) had anti-INF antibodies than those with RA (21.1%; P = 0.014). A significantly lower proportion of patients receiving concomitant DMARDs (16.5%) developed ADA than those on monotherapy (26.4%; P < 0.05). Conclusion: In patients with RA or SpA and secondary failure, the development of ADA against ADL or INF, but not ETN, appears to be one of the main reasons for secondary treatment failure, but not the only one. Further investigations are needed to determine other causes of anti-TNF failure.
Objectives: The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response. Methods: This was a cross-sectional, observational study of patients with active RA or SpA experiencing secondary failure to etanercept (ETN), infliximab (INF) or adalimumab (ADL). Concomitant non-biologic DMARDs were permitted. Serum anti-TNF and ADA levels were measured with two-site ELISA. Results: Among 570 evaluable patients, those with RA (n = 276) were mostly female (80 vs 39%), older (56 vs 48 years), received concomitant DMARDs (83 vs 47%) and had maintained good clinical disease control for longer (202 vs 170 weeks) compared with patients with SpA (n = 294). ADA were found in 114/570 (20.0%) patients; 51/188 (27.1%) against INF and 63/217 (29.0%) against ADL; none against ETN. Of these 114 patients, 92 (81%) had no detectable serum drug concentrations. Proportionately more patients with SpA (31.3%) had anti-INF antibodies than those with RA (21.1%; P = 0.014). A significantly lower proportion of patients receiving concomitant DMARDs (16.5%) developed ADA than those on monotherapy (26.4%; P < 0.05). Conclusion: In patients with RA or SpA and secondary failure, the development of ADA against ADL or INF, but not ETN, appears to be one of the main reasons for secondary treatment failure, but not the only one. Further investigations are needed to determine other causes of anti-TNF failure.
Authors: Xiaomei I Liu; André Dallmann; Yow-Ming Wang; Dionna J Green; Janelle M Burnham; Beatrice Chiang; Perry Wu; Mark Sheng; Kelley Lu; John N van den Anker; Gilbert J Burckart Journal: J Clin Pharmacol Date: 2019-03-13 Impact factor: 3.126
Authors: Juan J Alegre-Sancho; Xavier Juanola; José M Rodríguez-Heredia; Javier Manero; Ignacio Villa-Blanco; Ana Laiz; María J Arteaga; Luis Cea-Calvo; Carlos M González Journal: Medicine (Baltimore) Date: 2021-04-02 Impact factor: 1.817
Authors: Nils Bolstad; Hilde Berner Hammer; Johanna Elin Gehin; Silje Watterdal Syversen; David John Warren; Guro Løvik Goll; Joseph Sexton Journal: RMD Open Date: 2021-12
Authors: Ian R White; Sarah E Kleinstein; Christophe Praet; Chris Chamberlain; Duncan McHale; Jessica M Maia; Pingxing Xie; David B Goldstein; Thomas J Urban; Patrick R Shea Journal: PLoS One Date: 2022-04-12 Impact factor: 3.240
Authors: Zuben E Sauna; Susan M Richards; Bernard Maillere; Elizabeth C Jury; Amy S Rosenberg Journal: Front Immunol Date: 2020-10-29 Impact factor: 7.561